Non-Small Cell Lung Cancer
Advertisement
The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Learn more about outcomes from the first minimal residual disease analysis of the DART trial.
Dr. Archambault discusses the safety and effectiveness of cemiplimab plus chemotherapy for first-line treatment of aNSCLC.
Dr. Conkling shared his research insights on PD-L1 testing practices for mNSCLC within US community oncology settings.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about oncology referrals in NSCLC.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about recent NSCLC innovations.
Sanjay Juneja, MD, directed a discussion with Dr. Liu, Dr. Das, and Dr. Singhi on key updates in the field of NSCLC.
Jessica Bauman, MD, discusses a new analysis of the REACH PC study that she presented at ASCO 2025.
Dr. Liu weighs in on the CheckMate 816 data presented at the 2025 ASCO Annual Meeting.
The approval is for adults who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Stephen Liu, MD, shares his insights on the recent approval, the data behind it, and what the future may hold.
Sanjay Juneja, MD, was joined by lung cancer experts Dr. Liu, Dr. Das, and Dr. Singhi to discuss critical ASCO 2025 data.
Dr. Califano discusses what the study showed about baseline mechanisms of resistance to osimertinib and associated outcomes.
Local therapy is recommended by NCCN guidelines, but how it is used in oligoprogressive disease is not well described.
The organization also granted priority review, breakthrough designation, and orphan drug designation to the application.
Mariano Provencio, MD, PhD, presented the results of CheckMate 77T as a late-breaking abstract at ASCO 2025.
Phase 2 of the study investigated the targeted therapy in treatment-naive patients with stage III ALK-positive disease.
Patrick M. Forde, MD, presented the late-breaking abstract during an oral abstract session at the 2025 ASCO Annual Meeting.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.